Last updated 2026-07-27
- Went public on TASE (BLRX), Feb 2007
- Acquired Agalimmune for $6M, Mar 2017
- Raised $57M Follow-on PO, Feb 2007
Total raised
$123.0M
Last: Debt Financing 2024-04
Stage
Public
Founded
2003
Headcount
24
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences
About
BioLineRx is a publicly traded drug development company headquartered in Israel. It focuses on identifying, in-licensing, and developing therapeutic candidates, primarily in oncology and rare diseases. The company's main activities include the development and commercialization of innovative therapeutic solutions, leading promising compounds through preclinical and clinical trials, and partnering with other companies for further development and commercialization.
Funding history · 21 rounds · $123.0M total
2025-07
Follow-on PO
Undisclosed
2025-01
Follow-on PO
Undisclosed
2024-04
Follow-on PO
Undisclosed
2022-09
Follow-on PO
Undisclosed
2021-09
Follow-on PO
Undisclosed
2021-01
Follow-on PO
Undisclosed
2020-07
Follow-on PO
Undisclosed
2019-02
Follow-on PO
Undisclosed
2017-10
Follow-on PO
Undisclosed
2017-04
Follow-on PO
Undisclosed
2015-03
Follow-on PO
Undisclosed
2014-03
Follow-on PO
Undisclosed
2013-08
Follow-on PO
Undisclosed
2013-02
Follow-on PO
Undisclosed
2012-08
Follow-on PO
Undisclosed
2012-03
Follow-on PO
Undisclosed
2007-02
Follow-on PO
$57.0M
2005-08
B Round
$9.0M
★ Pitango VC★ Giza Venture Capital★ Teva Pharmaceutical Industries
2004-12
Grant
$21.0M
2004-04
A Round
$4.0M
★ Star Ventures★ Yehuda Zisapel (Late)
2003
Seed
$32.0M
★ Teva★ Orbimed★ Yehuda Zisapel★ Hadasit Bio-Holdings★ Jerusalem Development Authority
Headcount over time
From 56 (2018-08) to 47 (2026-03) · -9 (-16%) · 52 points · source: Finder history + radar grounding
Q&A
- What was BioLineRx's most recent funding event?
- In April 2025, BioLineRx completed a Public Offering, raising $4,870,000.
- When did BioLineRx go public on the TASE and NASDAQ?
- BioLineRx went public on the TASE in April 2007 and on NASDAQ in March 2014.
- What was the amount of the Public Offering in March 2015 and its valuation?
- In March 2015, BioLineRx had a Public Offering on NASDAQ with a valuation of $72,300,000. The amount raised was not specified in the public offerings data.
- What is BioLineRx's primary focus in drug development?
- BioLineRx is a biopharmaceutical company focused on developing therapies primarily in oncology and rare diseases.
- What was the amount of the Public Offering in April 2017 and its valuation?
- In April 2017, BioLineRx had a Public Offering on NASDAQ, raising $25,000,000 with a valuation of $69,000,000.
- What is the employee count range for BioLineRx?
- BioLineRx has an employee count in the 11-50 range.
- When did BioLineRx acquire Agalimmune and for what amount?
- BioLineRx acquired Agalimmune in March 2017 for $6,000,000.
- What is the total amount of funding BioLineRx has raised to date?
- BioLineRx has raised a total of $120,000,000 USD.
- What was the most recent debt financing round for BioLineRx?
- The most recent debt financing round for BioLineRx was in April 2024, raising $20,000,000.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
viral-diseasescancerinflammatory-diseasespharma-companiesdrug-discoverypharmaceuticalscancer-therapyimmunotherapyoncology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biolinerx.com |
|---|---|
| linkedin.com/company/112275 | |
| facebook.com/BioLineRx-786986118113858 | |
| YouTube | youtube.com/channel/UCjC1p4AbGeSzk1MjVaTEbAQ |
| Wikipedia | en.wikipedia.org/wiki/BioLineRx |
| Wikidata | wikidata.org/wiki/Q4914627 |
Identifiers & details
| Legal name | BioLineRx Ltd. |
|---|---|
| Founded | 2003 |
| Employees (exact) | 24 |
| Market cap | $13.1M |
| Status reason | Public on TASE on Apr, 2007;Public on NASDAQ on Mar, 2014; |
| Wikidata QID | Q4914627 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Agalimmune | 2017-03 | $6.0M |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2007-02 | TASE | BLRX | $50.0M |
| ADR Listing | 2011-07 | NASDAQ Capital Market | BLRX | |
| Public Offering | 2015-03 | NASDAQ | BLRX | |
| Public Offering | 2017-04 | NASDAQ | BLRX | $25.0M |
Radar intelligence
Patents
| EPO | 31 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | biolinerx.com |
|---|
Wikidata
| QID | Q4914627 |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513398750 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2003-04-02 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2005 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | המעיין 2 מודיעין-מכבים-רעות |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-06 | עדכון שעבוד |